1. Home
  2. Wim Van Molle
  3. Wim Van Molle

Primary tabs

Search
Limit to
Export 80 results:
Filters: Author is Wim Van Molle
2013
Regulatory issues regarding manufacture and control of vaccine adjuvants. The EU situation., Van Molle, Wim, Brusselmans Koen, Tesolin L., and Waeterloos Geneviève , Modern Vaccines/adjuvants Formulation: Impact On Future Development, 17/5/2013, Issue Herriot,J., Vanden Bossche,G., Lausanne, Switserland, (2013)
2012
Release testing by manufacturers & Ph.Eur. compliance: lessons learnt for competent authorities. A case study: the Extractable Volume, Van Molle, Wim, and Waeterloos Geneviève , Annual OMCL meeting, 13/6/2012, Issue EDQM, NA, (2012)
2010
Implementation over the past 20 years of the 3R's principle for batch release at the Scientific Institute of Public Health, Belgium (IPH)., Van Molle, Wim, Maes A., Ribaucour F, and Waeterloos Geneviève , Quality of medicines in a globalised world: dreams and reality, 15/10/2010, Issue European Directorate for the Quality of Medicines & HealthCare (EDQM),Council of Europe, Number 99, Prague, Czech Republic, p.98 - 99, (2010)
Testing and release of Synflorix ® monovalent conjugated bulks: update after 1 year of a complex vaccine with complex testing, Van Molle, Wim , Annual OMCL meeting, 2010, Issue EDQM, Split, Croatia, (2010)
2009
Implementation of Synflorix® monovalent bulk testing, Van Molle, Wim , Annual OMCL meeting, 2009, Issue EDQM, Vienna, Austria, (2009)

QR code

QR code for this page URL